Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin

Abstract Using a conditioned avoidance procedure in rats, the present study examined the ability of 8-OH-DPAT, ritanserin, and prazosin to alter the effects of the dopamine antagonists, raclopride and haloperidol, on avoidance- and on escape responding. The 5-HT1A agonist 8-OH-DPAT (0.16 mg/kg) significantly enhanced the inhibitory effects of both raclopride and haloperidol on the conditioned avoidance response and produced a small enhancement of the effects of haloperidol on escape failures. The α1-adrenoceptor antagonist prazosin (0.63 mg/kg) significantly enhanced the effects of raclopride on the conditioned avoidance response, but enhanced the effects of only a single dose of haloperidol; prazosin did not alter the effects of either dopamine antagonist on escape failures. The 5-HT2 antagonist ritanserin (0.16 mg/kg) failed significantly to alter the effects of the dopamine antagonists examined here. These findings suggest that blockade of 5-HT2 receptors may not enhance the antipsychotic efficacy of D2-like antagonists. Further, they confirm previous findings with respect to interactions between 5-HT1A agonists and neuroleptics, and support the hypothesis that combined 5-HT1A agonist/D2-like antagonist properties may be of clinical importance.

[1]  C J Niemegeers,et al.  Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? , 1966, Arzneimittel-Forschung.

[2]  S. Gershon,et al.  MJ 9022: correlation between neuroleptic potential and stereotypy. , 1975, Current therapeutic research, clinical and experimental.

[3]  S. Matthysse DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE* , 1975 .

[4]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[5]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[6]  A. Uzan,et al.  Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic postsynaptic receptors , 1979, Neuropharmacology.

[7]  R. Baldessarini,et al.  Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. , 1980, Annual review of neuroscience.

[8]  C. Marsden,et al.  The pathophysiology of extrapyramidal side-effects of neuroleptic drugs , 1980, Psychological Medicine.

[9]  Sakutaro Tadokoro,et al.  Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses , 1981, Pharmacology Biochemistry and Behavior.

[10]  J. Arnt,et al.  Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. , 2009, Acta pharmacologica et toxicologica.

[11]  M. Sanghera,et al.  Dopamine receptor antagonism by the novel antianxiety drug, buspirone , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  B. Bunney,et al.  Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  S O Ogren,et al.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.

[14]  J. Hyttel,et al.  Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. , 2009, Acta pharmacologica et toxicologica.

[15]  C. Braestrup,et al.  Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. , 1986, European journal of pharmacology.

[16]  M. Latranyi,et al.  Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action. , 1987, European journal of pharmacology.

[17]  L. Cervo,et al.  8-hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis , 1988, Neuropharmacology.

[18]  B. McMillen,et al.  Reversal of neuroleptic‐induced catalepsy by novel aryl‐piperazine anxiolytic drugs , 1988, The Journal of pharmacy and pharmacology.

[19]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[20]  S. Ahlénius Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. , 1989, Pharmacology & toxicology.

[21]  J. Leysen,et al.  Receptor occupancy by ritanserin and risperidone measured using ex vivo autaradiography , 1989, Brain Research.

[22]  L. Adler,et al.  Effects of buspirone in seven schizophrenic subjects. , 1990, Journal of clinical psychopharmacology.

[23]  J. Lieberman,et al.  Update on the clinical efficacy and side effects of clozapine. , 1991, Schizophrenia bulletin.

[24]  Neuroleptic drugs and dopamine receptors. , 1991 .

[25]  D. Goff,et al.  An open trial of buspirone added to neuroleptics in schizophrenic patients. , 1991, Journal of clinical psychopharmacology.

[26]  A. Cools,et al.  The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. , 1991, European journal of pharmacology.

[27]  Eric R. Marsh,et al.  Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine? , 1992, British Journal of Psychiatry.

[28]  F. Colpaert,et al.  Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors , 1992, Neuroscience & Biobehavioral Reviews.

[29]  B. Ellenbroek,et al.  Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. , 1993, Pharmacology & therapeutics.

[30]  W. Koek,et al.  Binding of antipsychotic drugs at α1A- and α1B-adrenoceptors: risperidone is selective for the α1B-adrenoceptors , 1993 .

[31]  W. Koek,et al.  Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. , 1993, European journal of pharmacology.

[32]  T. Barnes,et al.  Acute exacerbation of psychosis with buspirone? , 1993, Journal of psychopharmacology.

[33]  P. Botter,et al.  Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia , 1993, British Journal of Psychiatry.

[34]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[35]  I. Lucki,et al.  Serotonergic involvement in haloperidol-induced catalepsy. , 1993, The Journal of pharmacology and experimental therapeutics.

[36]  A. Cools,et al.  Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test , 1994, British journal of pharmacology.

[37]  C. Czudek,et al.  Common profile of D1 receptor antagonists and atypical antipstchotic drugs revealed by analysis of dopamine turnover , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  A. Cools,et al.  Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. , 1994, European journal of pharmacology.

[39]  A. Cools,et al.  The Role of Serotonin Receptor Subtypes in the Behavioural Effects of Neuroleptic Drugs. A Paw Test Study in Rats , 1994, The European journal of neuroscience.

[40]  P. Bonaventure,et al.  In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. , 1995, Japanese journal of pharmacology.

[41]  J. Peuskens Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol , 1995, British Journal of Psychiatry.

[42]  Peer review of risperidone in the treatment of patients with chronic schizophrenia. A multinational, multicenter, double-blind, parallel-group study versus haloperidol response , 1995 .